About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials LymphomaCleveland

Lymphoma Clinical Trials in Cleveland

Find 345 clinical trials for lymphoma near Cleveland, Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Cleveland

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 201-220 of 345 trials

CompletedS0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop…NCT00070018·Anchorage, Alaska and 47 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

UnknownCombination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00053105·Tucson, Arizona and 6 others

Active not recruitingSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic…NCT02227251·Tucson, Arizona and 174 others

CompletedStudy of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesThis study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies.NCT02576496·Phoenix, Arizona and 17 others

TerminatedLong-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.NCT05645744·Orange, California and 4 others

AvailableExpanded Access Program for OOS Obe-celThe purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured from their blood…NCT06799221·Gilbert, Arizona and 31 others

UnknownCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaThe purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination…NCT02481310·Chicago, Illinois and 4 others

CompletedTemsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaThis phase I trial studies the side effects and the best dose of temsirolimus when given together with dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and…NCT01403415·Birmingham, Alabama and 30 others

Active not recruitingRituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.NCT01415752·Anchorage, Alaska and 417 others

CompletedSafety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's LymphomaThis study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.NCT00354926·Birmingham, Alabama and 10 others

CompletedSafety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersThis is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders.NCT00788684·Tucson, Arizona and 5 others

CompletedS0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00005089·Mobile, Alabama and 91 others

Approved for marketingAxicabtagene Ciloleucel Expanded Access StudyA multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.NCT03153462·Duarte, California and 14 others

Active not recruitingObinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaThis phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular…NCT03269669·Anchorage, Alaska and 428 others

CompletedRituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00274924·Palo Alto, California and 103 others

TerminatedGene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaRATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.NCT00003567·Cleveland, Ohio

Active not recruitingTesting CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaThis phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide…NCT04799275·Tucson, Arizona and 175 others

TerminatedA Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.NCT05144009·Tucson, Arizona and 40 others

Active not recruitingA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.NCT04245839·Santa Monica, California and 48 others

CompletedPhotodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis FungoidesRATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.NCT00103246·Cleveland, Ohio

PreviousPage 11 of 18Next

Other Conditions in Cleveland

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia